Journal of Microbiology

The Microbiological Society of Korea (한국미생물학회)
권호 표지

Natural Iminosugar Derivatives of 1-Deoxynojirimycin Inhibit Glycosylation of Hepatitis Viral Envelope Proteins

  • Jacob, James R. (Department of Clinical Sciences, College of Veterinary Medicine, Cornell University) ;
  • Mansfield, Keith (Division of Primate Resources, New England Regional Primate Research Center, Harvard Medical School) ;
  • You, Jung-Eun (Department of Life Sciences, The University of Suwon) ;
  • Tennant, Bud C. (Department of Clinical Sciences, College of Veterinary Medicine, Cornell University) ;
  • Kim, Young-Ho (Department of Life Sciences, The University of Suwon)
  • Published : 2007.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

A silkworm (Bombyx mori L.) extract known to contain naturally occurring iminosugars, including 1-deoxynojirimycin (1-DNJ) derived from the mulberry tree (Morus alba L.), was evaluated in surrogate HCV and HBV in vitro assays. Antiviral activity of the silkworm extract and one of its purified constituents, 1-DNJ, was demonstrated against bovine viral diarrhea virus (BVDV) and GB virus-B (GBV-B), both members of the Flaviviridae family, and against woodchuck hepatitis virus (WHV) and hepatitis B virus (HBV), both members of the Hepadnaviridae family of viruses. The silkworm extract exhibited a 1,300 fold greater antiviral effect against BVDV in comparison to purified 1-DNJ. Glycoprotein processing of BVDV envelope proteins was disrupted upon treatment with the naturally derived components. The glycosylation of the WHV envelope proteins was affected largely by treatment with the silkworm extract than with purified 1-DNJ as well. The mechanism of action for this therapy may lie in the generation of defective particles that are unable to initiate the next cycle of infection as demonstrated by inhibition of GBV-B in vitro. We postulate that the five constituent iminosugars present in the silkworm extract contribute, in a synergistic manner, toward the antiviral effects observed for the inhibition of intact maturation of hepatitis viral particles and may complement conventional therapies. These results indicate that pre-clinical testing of the natural silkworm extract with regards to the efficacy of treatment against viral hepatitis infections can be evaluated in the respective animal models, in preparation for clinical trials in humans.

Keywords

References

  1. Asano, N. 2003. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 13, 93R-104R https://doi.org/10.1093/glycob/cwg090
  2. Asano, N., K. Oseki, H. Kizu, and K. Matsui. 1994. Nitrogen-inthe- ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J. Med. Chem. 37, 3701-3706 https://doi.org/10.1021/jm00048a006
  3. Asano, N., K. Oseki, E. Tomioka, H. Kizu, and K. Matsui. 1994. N-containing sugars from Morus alba and their glycosidase inhibitory activities. Carbohydr. Res. 259, 243-255 https://doi.org/10.1016/0008-6215(94)84060-1
  4. Asano, N., T. Yamashita, K. Yasuda, K. Ikeda, H. Kizu, Y. Kameda, A. Kato, R.J. Nash, H.S. Lee, and K.S. Ryu. 2001. Polyhydroxylated alkaloids isolated from Mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J. Agric. Food Chem. 49, 4208-4213 https://doi.org/10.1021/jf010567e
  5. Beames, B., D. Chavez, B. Guerra, L. Notvall, K.M. Brasky, and R.E. Lanford. 2000. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J. Virol. 74, 11764-11772 https://doi.org/10.1128/JVI.74.24.11764-11772.2000
  6. Block, T.M., X. Lu, A.S. Mehta, B.S. Blumberg, B.C. Tennant, M. Ebling, B. Korba, D.M. Lansky, G.S. Jacob, and R.A. Dwek. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med. 4, 610-614 https://doi.org/10.1038/nm0598-610
  7. Block, T.M., X. Lu, F.M. Platt, G.R. Foster, W.H. Gerlich, B.S. Blumber, and R.A. Dwek. 1994. Secretion of hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. USA 91, 2235-2239
  8. Branza-Nichita, N., D. Durantel, S. Carrouee-Durantel, R.A. Dwek, and N. Zitzmann. 2001. Antiviral effects of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J. Virol. 75, 3527-3536 https://doi.org/10.1128/JVI.75.8.3527-3536.2001
  9. Cavalletto, L., L. Chemello, C. Donada, P. Casarin, F. Belussi, E. Bernardinello, F. Marino, P. Pontisso, A. Gatta, and A. Alberti. 2000. The pattern of response to interferon alpha predicts sustained response to a 6-month alpha-INF and ribavirin retreatment for chronic hepatitis C. J. Hepatol. 33, 128-134 https://doi.org/10.1016/S0168-8278(00)80169-5
  10. Chisari, F.V. and C. Ferrari. 1997. Viral hepatitis, p. 745-778. In N. Nathanson (ed.), Viral pathogenesis. Lippincott-Raven Publishers, Philadelphia, PA, USA
  11. Chou, T.C. and P. Talalay. 1984. Quantitative Analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Reg. 22, 27-55 https://doi.org/10.1016/0065-2571(84)90007-4
  12. Corapi, W.V., R.O. Donis, and E.J. Dubovi. 1990. Characterization of a panel of monoclonal antibodies and their use in the study of the antigenic diversity of bovine viral diarrhea virus. Am. J. Vet. Res. 51, 1388-1394
  13. Crespo, J., J.L. Lozano, B. Carte, B. De Las Heras, F. De La Cruz, and F. Pons-Romero. 1997. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur. J. Clin. Infect. Dis. 16, 445-451 https://doi.org/10.1007/BF02471908
  14. Di Bisceglie, A.M. and B.R. Bacon. 1999. The unmet challenges of hepatitis C. Scientific American 281, 80-85
  15. Dobrinski, I., J.R. Jacob, B.C. Tennant, and B. Ball. 1999. Generation of an equine oviductal epithelial cell line for the study of sperm-oviduct interaction. Theriogenology 52, 875-885 https://doi.org/10.1016/S0093-691X(99)00179-X
  16. Durantel, D., N. Branza-Nichita, S. Carrouee-Durantel, T.D. Butters, R.A. Dwek, and N. Zitzmann. 2001. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998 https://doi.org/10.1128/JVI.75.19.8987-8998.2001
  17. Hoofnagle, J.H. and A.M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. New Engl. J. Med. 336, 337-356 https://doi.org/10.1056/NEJM199701303360504
  18. Jacob, G.S. 1995. Gylcosylation inhibitors in biology and medicine. Curr. Opin. Struct. Bool. 5, 605-611 https://doi.org/10.1016/0959-440X(95)80051-4
  19. Jacob, J.R., R.H. Liu, C. Roneker, F. Noronha, J.H. Hotchkiss, and B.C. Tennant. 1994. Characterization and immortalization of woodchuck hepatocytes isolated from normal and hepadnavirus infected woodchucks (Marmota monax). Exp. Cell Res. 212, 42-48 https://doi.org/10.1006/excr.1994.1116
  20. Jacob, J.R., I. Toshkov, B.E. Korba, P.J. Cote, W. DeLaney, J.L. Gerin, and B.C. Tennant. 2004. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res. In press
  21. Jarvis, B. and D. Faulds. 1999. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58, 101-141 https://doi.org/10.2165/00003495-199958010-00015
  22. Jassim, S.A.A. and M.A. Naji. 2003. Novel antiviral agents: a medicinal plant perspective. J. Appl. Micro. 95, 412-427 https://doi.org/10.1046/j.1365-2672.2003.02026.x
  23. Jen, J., M. Laughlin, C. Chung, S. Heft, M.B. Affrime, S.K. Gupta, P. Glue, and G. Hajian. 2002. Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. Clin. Pharmacol. Therapeutics 72, 349-361 https://doi.org/10.1067/mcp.2002.127112
  24. Joubert, P.H., C.P. Venter, H.F. Joubert, and I. Hillebrand. 1985. The effect of 1-deoxynojirimycin derivative on post-pradial blood glucose and insulin levels in healthy black and white volunteers. Eur. J. Clin. Pharmacol. 28, 705-708 https://doi.org/10.1007/BF00607920
  25. Khakoo, S., P.G. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G.M. Dusheiko. 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46, 563-570 https://doi.org/10.1046/j.1365-2125.1998.00836.x
  26. Kimura, M., F.J. Chen, N. Nakashima, I. Kimura, N. Asano, and S. Koya. 1995. Antihyperglycemic effects of N-containing sugars derived from Mulberry leaves in streptozocin-induced diabetic mice. J. Trad. Med. 12, 214-219
  27. Korba, B.E. and J.L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19, 55-70 https://doi.org/10.1016/0166-3542(92)90056-B
  28. Lanford, R.E., D. Chavez, B. Guerra, J.Y.N. Lau, Z. Hong, K.M. Brasky, and B. Beames. 2001. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J. Virol. 75, 8074-8081 https://doi.org/10.1128/JVI.75.17.8074-8081.2001
  29. Liang, T.J. 1999. Complementary and alternative medicine: The roots of healing. Gastroenterology 117, 1041 https://doi.org/10.1016/S0016-5085(99)70385-9
  30. Liaw, Y.F. 2001. Concurrent hepatitis B and C virus infection: is hepatitis C virus stronger? J. Gastroenterol. Hepatol. 16, 597-598 https://doi.org/10.1046/j.1440-1746.2001.02523.x
  31. Liu, J., L. Kjaergard, and C. Glund. 2002. Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Amer. J. Chinese Med. 30, 173-176 https://doi.org/10.1142/S0192415X0200017X
  32. Look, M.P., A. Gerard, G.S. Rao, T. Sudhop, H.P. Fischer, T. Sauerbruch, and U. Spengler. 1999. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res. 43, 113-122 https://doi.org/10.1016/S0166-3542(99)00041-8
  33. Lu, X., A. Mehta, R. Dwek, T. Butters, and T. Block. 1995. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virol. 213, 660-665 https://doi.org/10.1006/viro.1995.0038
  34. Martin, K.W. and E. Ernest. 2003. Antiviral agents from plants and herbs; a systemic review. Antivir. Ther. 8, 77-90
  35. McHutchison, J.G., S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht. 1998. Interferon alpha 2a alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England J. Med. 339, 1485-1492 https://doi.org/10.1056/NEJM199811193392101
  36. Mehta, A., B. Conyers, D.L.J. Tyrrell, K.A. Walters, G.A. Tipples, R. Dwek, and T.M. Block. 2002. Structure-activity relationship of a new class of anti-hepatitis B virus agents. Antimicro. Agents Chemo. 46, 4004-4008 https://doi.org/10.1128/AAC.46.12.4004-4008.2002
  37. Ouzounzov, S., A.D. Menta, T.M. Block, and R. Jordan. 2002. The combination of interferon ${\alpha}$-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy. Antiviral Res. 55, 425-435 https://doi.org/10.1016/S0166-3542(02)00075-X
  38. Pestka, S. 1986. Interferon standards and general abbreviations. Meth. Enzymol. 119, 14-23 https://doi.org/10.1016/0076-6879(86)19004-5
  39. Schuppan, D., J.D. Jia, B. Brinhaus, and E.G. Hann, 1999. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 30, 1099-1104 https://doi.org/10.1002/hep.510300437
  40. Schvarcz, R., Z.B. Yun, A. Sonnerborg, and O. Weiland. 1995. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46, 43-47 https://doi.org/10.1002/jmv.1890460110
  41. Seeff, L.B., K.L. Lindsay, B.R. Bacon, T.F. Kresina, and J.H. Hoofnagle. 2001. Complementary and alternative medicine in chronic liver disease. Hepatology 34, 595-603 https://doi.org/10.1053/jhep.2001.27445
  42. Stephensen, C.B., J.R. Jacob, R.J. Montali, R.J. Montali, E.D. Armes, M.J. Buchmeler, E. Muchmore, K.V. Holmes, and R.E. Lanford. 1991. Isolation of an arenavirus from a marmoset with callitrichid hepatitis and its serologic association with disease. J. Virol. 65, 3995-4000
  43. Strader, D.B. and H.J. Zimmerman. 2000. Complementary and alternative medicine in Hepatitis C, p. 363-386. In T.J. Liang and J.H. Hoofnagle (ed.), Biomedical Research Reports; Hepatitis C. Academic Press, New York, NY, USA
  44. Tolle, T.K., D. Glebe, M. Linder, D. Linder, S. Schmitt, R. Geyer, and W.H. Gerlich. 1998. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J. Virol. 72, 9978-9985
  45. Tsiang, M., J.F. Roonex, J.J. Toole, and G.S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29, 1863-1869 https://doi.org/10.1002/hep.510290626
  46. Vilcek, J. and G.C. Sen. 1996. Interferons and other cytokines, p. 375-399. In B.N. Fields, D.M. Knipe, and P.M. Howley (ed.), Fields Virology. Lippincott-Raven Publishers, Philadelphia, PA, USA
  47. Wu, S.F., C.J. Lee, C.L. Liao, R.A. Dwek, N. Zitzmann, and Y.L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 67, 3596-3604
  48. Zitzmann, N., A.S. Mehta, S. Carrouee, T.D. Butters, F.M. Platt, J. McCauley, B.S. Blumberg, R.A. Dwek, and T.M. Block. 1999. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA 96, 11878-11882